Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Troubled Teva has been preparing employees for layoffs, but the final plan will reshape the generic drug giant entirely with 14,000 jobs being cut in a scramble to stabilize the company. Every business area and geography will be affected.
You may also be interested in...
Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone
A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.
A Trough Year For Teva, With A Turning Point Targeted For 2020
As the company's turnaround plan matures, 2019 will remain a year of cost-cutting and focus as it looks to pay down debt and stabilize its financials. "We'll be focused on optimizing our own business rather than adding new businesses," CEO Schultz said.
J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: US generics see gains, researcher calls for more tech transfer, and biotech investor sentiment rises as big deals bring optimism – among other items from the last day of this year's JPM.